Nano-Satellite Complexes for Cold Tumor Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches, such as checkpoint blockade, have limited efficacy in treating 'cold' tumors that are hypo-immunogenic and resistant to immune cells, with response rates below 20% for head and neck squamous cell carcinoma, highlighting the need for novel mechanisms to enhance anti-tumor immunity.
Innovation Solution
Development of nano-satellite complexes and serum albumin carrier complexes that incorporate a biocompatible coating, satellite particles, antigenic components, and type I interferon agonists to modulate antigen-specific immune responses, potentially overcoming tumor immunogenicity by enhancing type I interferon signaling and APC maturation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If checkpoint blockade is used to treat cold tumors, then effector function of tumor infiltrating lymphocytes is restored, but clinical response rate remains below 20% due to tumor hypo-immunogenicity
Solution Approach 1:
The patent applies preliminary action by using type I interferon agonists to pre-condition the tumor microenvironment before checkpoint blockade therapy. This activates dendritic cells and promotes antigen presentation in advance, transforming cold tumors into hot tumors that are more responsive to subsequent immunotherapy, thereby overcoming the hypo-immunogenicity barrier that limits checkpoint blockade efficacy
Solution Approach 2:
The patent introduces type I interferon agonists as an intermediary substance that mediates between the checkpoint blockade therapy and the tumor microenvironment. This intermediary activates immune cells and enhances antigen presentation, bridging the gap between the checkpoint inhibitor and the hypo-immunogenic tumor, thereby improving the overall therapeutic effect
2Reliability
If mono-therapy with checkpoint inhibitors is administered, then treatment simplicity is maintained, but therapeutic efficacy is limited in hypo-immunogenic tumors
Solution Approach 1:
The patent merges type I interferon agonist therapy with checkpoint blockade into a unified treatment regimen. By combining these two therapies, the patent achieves synergistic effects where the interferon agonist primes the immune system and enhances antigen presentation, while the checkpoint inhibitor releases brake signals, together overcoming tumor hypo-immunogenicity and improving therapeutic efficacy beyond what either therapy could achieve alone
3Reliability
If conventional immunotherapy is used, then treatment accessibility is maintained, but ability to elicit tumor antigen-specific cytotoxic T lymphocytes fails in cold tumors
Solution Approach 1:
The patent applies local quality by delivering type I interferon agonists directly to the tumor microenvironment, creating a localized immune-activating zone. This localized intervention selectively enhances dendritic cell activation and antigen presentation at the tumor site without affecting the entire organism, thereby enabling CTL production in previously refractory cold tumors while maintaining treatment safety
Data Source
AI summary
The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and/or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.